Mark C. Schneyer, EVP, Chief Financial Officer at Acadia Pharmaceuticals, sold ACAD on Aug 6, 2026
Data as of Oct 27
▼ SELL$273K9,292 shares at $29.34Mark C. Schneyer EVP, Chief Financial OfficerACAD Acadia Pharmaceuticals Inc
- Traded
- Aug 6, 2026
- Disclosed
- Aug 7, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ACAD since disclosure
−30.9%
after the sale
Similar stocks (XLV) since disclosure
+8.1%
XLV — its sector index fund
Change in closing price from Aug 7, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLMark C. Schneyer EVP, Chief Financial OfficerACAD Acadia Pharmaceuticals Inc$145Kdisclosed Aug 7 · filed 1 day after the trade
- ▼ SELLMark C. Schneyer EVP, Chief Financial OfficerACAD Acadia Pharmaceuticals Inc$170Kdisclosed Aug 7 · filed 2 days after the trade